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ABSTRACT 
The present research work emphasized on evaluates the Phytochemical & Pharmacological activities of the fruits of Scindapsus 
Officinalis (Roxb) (Araceae). The fruits of the plant were shade dried, reduced to coarse powder with the help of grinder was subjected to 
successive soxhlet extraction with Petroleum Ether and 90% v/v Ethanol (Emparta). The various extracts were then subjected to preliminary 
phytochemical screening which revealed the presence of flavonoids, saponins, tannins, phenols, carbohydrate, lipids, alkaloids & steroids. 
Selection of active extract for in vivo studies was based on preliminary phytochemical tests and in vitro glucose diffusion inhibition potential 
and accordingly, ethanolic extracts were chosen for further studies. The pharmacological screening included evaluation of the antidiabetic and 
hypolipidemic activity of ethanolic extracts (200mg/kg and 400mg/kg b.w) on Streptozotocin-induced diabetic rats. The ethanolic extract was 
found to be more effective and brought about significant antidiabetic & hypolipidemic potential. This was due to the presence of one or more 
phytoconstituents present in ethanol extract.  
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INTRODUCTION: 
The occurrence of diabetes is hastily rising all over the world 
at a frightening rate. Over the past 30 years, the status of 
diabetes has changed from being measured as a kind 
disorder of the old to one of the main causes of morbidity 
and mortality disturbing the childhood and middle aged 
people. It is essential to note that the increase in prevalence 
is seen in all six populated continents of the globe.[1] 
Diabetes is deadly disease in both developed and developing 
countries. In 2000, there were a probable 175 million people 
with diabetes universal and by 2030, the projected estimate 
of diabetes is 354 million.  
S. officinalis is a communal plant in tropical forests of many 
parts of India, Myanmar, China and Nepal. In India, the plant 
is cultivated for its fruits at Midnapur, Bengal and is 
originate in southern cities of Calicut and Cochin. It is also 
existing in Rosa thicket in managed sal (Shorea 
robusta Gaertn.) forests of Gorakhpur region.[2,3]. 
 
 
MATERIALS AND METHOD: 
Collection and identification  
Plant was collected from the India, during the months of 
august and September 2017. Taxonomic and ethno 
medicinal identification of the collected fruits of plant by Mr. 
S.L. Meena (Deputy Director of botanical survey of india, 
near khem ka kuaon, Nandan Van, Jodhpur-324008) 
Preparation of plant material 
The fruits of plant were shade dried, reduced to coarse 
powder with the help of grinder and stored in airtight 
container till further use. 1 kg of powdered drugs were 
packed in soxhlet apparatus and continuously extracted with 
petroleum ether to defat the fruits powder. Petroleum ether 
was removed from the powdered defatted drug, which was 
then extracted with ethanol (90%).  The extracted were 
evaluated for anti-diabetic activity, then most bio potent 
extract further fractioned with hexane, chloroform and 
ethanol. The solvents were removed from each extract and 
fraction by distillation and the last traces of solvent being 
removed under reduced pressure. The extracts and fractions 
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were weighed and their % value was recorded and also the 
physical appearance, color and odor was evaluated and 
recorded and thereafter, extracts were stored in refrigerator 
for further experimental work [4-7]. 
Quantitative determination of the chemical 
constituents:  
Total phenols Determination:  
The total content of phenols in the crude ethanol extract was 
determined using a modified Folin-Ciocalteu colorimetric 
method with Gallic acid as a standard. The extract solution in 
DMSO (700 μL) was transferred to a 10 mL volumetric flask, 
the Folin-Ciocalteu reagent (400 μL) was added and after 3 
min, each flask was made up to the mark with sodium 
carbonate (Na2CO3) solution (75 g/L). After 2 hours, the 
suspension was centrifuged (5000 r.p.m., 5 min) and the 
absorbance of the solution was measured at 760 nm. The 
total phenolic content was expressed as a Gallic acid 
equivalent (GAE) in g/100 g of dry extract. Data are reported 
as mean ± SD for three replicates. The total phenol was 
calculated.[8] 
Total alkaloid determination 
5 g of the sample was weighed and transfer into a 250 ml 
beaker and 200 ml of 10% acetic acid in ethanol [9] was 
added and covered and allowed to stand for 4 h. This was 
filtered and the extract was concentrated on a waterbath to 
one-quarter of the original volume. Concentrated 
ammonium hydroxide was added drop wise to the extract 
until the precipitation was complete. The whole solution was 
allowed to settle and the precipitated was collected and 
washed with dilute ammonium hydroxide and then filtered. 
The residue is the alkaloid, which was dried and weighed. 
The total alkaloid was calculated.[10] 
Total tannin determination 
500 mg of the sample was weighed into a 50 ml plastic 
bottle. 50 ml of distilled water was added and shaken for 1 h 
in a mechanical shaker. This was filtered into a 50 ml 
volumetric flask and made up to the mark. Then 5 ml of the 
filtered was pipetted out into a test tube and mixed with 2 
ml of 0.1 M Ferric chloride in 0.1 N HCl and 0.008 M 
potassium ferrocyanide. The absorbance was measured at 
120 nm within 10 min. The total tannin was calculated.[11] 
Total flavonoid determination 
10 g of the plant sample was extracted repeatedly with 100 
ml of 80% aqueous methanol at room temperature. The 
whole solution was filtered through whatman filter paper No 
42 (125 mm). The filtrate was later transferred into a 
crucible and evaporated into dryness over a water bath and 
weighed to a constant weight. [12] 
Thin layer chromatography (TLC) 
Chromatography is widely used for the separation, isolation, 
identification, and quantification of components in a 
mixture. 
Preparation of plates 
Slurry of silica gel G and distilled water was prepared in a 
pestle with continuous triturating with mortar. The slurry 
was spread evenly on clean grease free glass plates. The 
plates were dried in air and thereafter heated in oven at 110 
0C for about 30 minutes to activate them.[13] 
Preparation of samples 
 Approximately 10 mg of material was dissolved in 
respective solvents and was used for spotting on TLC plates. 
The TLC profile was examined to determine variation in 
band size and color intensity between the Ethanolic extract 
and its two fraction .The observation indicate that variations 
are present amongst Ethanolic extract, Ethanolic fraction, 
Hexane fraction and chloroform fraction. The TLC study was 
done by using different solvent system for each fraction 
separately and the compounds were detected by sun light, in 
iodine vapours, vanillin sulfuric acid reagent and long 
UV.[14-18] 
Determination of the antidiabetic effect of the 
scindapsusofficinalis in rats 
Drugs and Chemicals  
Scindapsus officinalis and streptozotocin were purchased 
from Sigma-Aldrich. Glucose kits were purchased from 
Agappe Diagnostics Ltd., India. All other chemicals were 
obtained from Hi Media  (Mumbai, India) and SD Fine 
Chemicals Limited (Mumbai, India). 
Experimental Induction of Diabetes     
                                  
Diabetes was induced in rats with an intraperitoneal 
injection of STZ ((40 mg/kg bwt) freshly prepared in 0.1 M 
sodium citrate buffer (PH 7) after overnight  fasting. The rats 
exhibited diabetes after 5 days (i.e., fasting blood glucose 
concentration, >300 mg/dl) and were selected for the 
treatment with Scindapsus officinalis. dissolved in water. 
[19] 
Sample Collection     
                                                     
Blood samples were collected from orbital plexus by 
pricking a needle under ketamine anesthesia. Rats had free 
access to water and food while in metabolic cages. The 
change in body weight of the rats was recorded at regular 
intervals throughout the study. At the end of the experiment, 
all the animals were starved for 16 h and anaesthetized by 
intra-peritoneal injection of ketamine (30mg/kg body 
weight) and sacrificed by cervical decapitation. Blood 
samples were collected and the tissue was removed 
immediately, washed with ice-cold physiological saline to 
remove the blood clot and other tissue materials. For 
histopathological studies, a piece of 1 cm3 of tissue was cut 
and placed immediately in phosphate buffered formal saline 
pH 7.4[20] 
Separation of Serum  
The blood sample collected by centrifuge tubes method in 
small vials in the freezer for the purpose of biochemical 
investigations. 
Observations 
Following observations carried out during the study period 
will be reported. Additional observations/parameters may 
be evaluated based on need at the discretion of study 
director and will be documented accordingly viz; Morbidity 
and Mortality Observations, Clinical Observations, Body 
Weight: Body weights will be recorded on the day 1 of 
acclimatization and on the day of randomization; on Day 1 
(prior to dosing of STZ) and 5th day after STZ induction on 
Days 7, 14, 21, 28 and 29 (fasting condition) during the 
experimental period. 
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Gross Pathology 
At the end of the observation period, all animals will be 
euthanized by chloroform asphyxiation followed by 
exsanguination and subjected to gross necropsy, including 
examination of external surfaces, orifices and 
thoracic/abdominal cavities. 
Biochemical Studies 
Estimation of Blood Glucose 
Glucose was estimated by the method of Trinder (1969) 
using reagent kit. A 10 μl of serum, standard and distilled 
water (blank) were taken in three separate tubes. One ml of 
the enzyme reagent was added, mixed and kept at 37ºC for 
15 min. The colour development was read at 510 nm against 
a reagent blank in a UV-Visible spectrophotometer. The 
values are expressed as mg/dl.[21] 
Antihyperglycemic activity of ethanolic extracts in 
glucose-loaded animals (oral glucose tolerance test) 
The oral glucose tolerance test (OGTT) measures the body's 
ability to use main source of energy i.e. glucose. OGTT is to 
simplify and facilitate the diagnosis of diabetes (Luzi, 1998). 
This method is frequently referred to as physiological 
induction of diabetes mellitus because the blood glucose 
level of the animal is fleetingly increased with no damage to 
the pancreas. An oral glucose tolerance test (OGTT) was 
performed on diabetic rats by feeding glucose (5 g/kg) per 
os. Animals were deprived of food 18 h before and during 
the experiment, but were allowed free access to water. They 
were divided into 5 groups of 6 rats each. Group I served as 
normal control, Group II served as solvent control and 
received only vehicle (Tween + water - 2 ml/kg b.w.) 
through the oral route. Group III received glibenclamide (5 
mg/kg b.w.). Groups IV to V received the alcohol extracts of 
Scindapsus officinalis  Roxb.at a dose of 200 and 400 mg/kg 
b.w., respectively, through oral route. The blood glucose 
level was determined before drug and glucose 
administration (−1 and 0 h, respectively) and subsequently 
at 0.5, 1, 2 and 3h after.[22] 
Effect of the ethanolic extracts on blood glucose level in 
streptozocin induce hyper glycemic rats 
The acclimatized animals were kept fasting for 24 h with 
water ad libitum and injected intraperitoneally a dose of 150 
mg/kg of streptozocin in normal saline. After 1 h, the 
animals were provided feed ad libitum. The blood glucose 
level was checked before streptozocin and 24 h after 
streptozocin as above. Animals were considered diabetic 
when the blood glucose level was raised beyond 200 
mg/100 ml of blood. This condition was observed at the end 
of 72 h after streptozocin. The animals were segregated into 
five groups of six rats in each. Group I served as normal 
control, Group II served as diabetic control and received 
vehicle (2 ml/kg) through the oral route. Group III received 
glibenclamide (5 mg/kg). Groups IV to V ethanolic extracts 
of Scindapsus officinalis  Roxb.at doses of 200 and 400 
mg/kg. Blood glucose level of each rat was estimated at 1, 2, 
4, 6, 8 and 10 h, respectively.[23] 
Antihyperglycemic activity of ethanolic extract in 
glucose-loaded animals (oral glucose tolerance test) 
An oral glucose tolerance test (OGTT) of ethanolic extract 
was performed on diabetic rats by administration of glucose 
(5 g/kg) per os. Animals were deprived of food 18 h before 
and during the experiment, but were allowed free access to 
water. They were divided into four groups of 6 rats each. 
Group I solvent control and received only vehicle (Tween + 
water - 2 ml/kg b.w.), Group II received standard drug 
glibenclamide (5 mg/kg b.w.). Groups III & IV received the 
ethanolic extract of Scindapsus officinalis Roxb. at a dose of 
200 and 400 mg/kg b.w., respectively, through oral route. 
The blood glucose level was determined before drug and 
glucose administration (-1 and 0 h, respectively) and 
subsequently at 1, 2 and 3h after.[24] 
RESULT AND DISCUSSION: 
Table 1. Physical parameters of Scindapsus officinalis  
Roxb. Fruits powder 
Studied parameters  Observation (% w/w) 
Loss on drying 6.9 
Total ash value 5.2 
Acid insoluble ash value 4.3 
Water soluble ash value 3.1 
Alcohol extractive value 16.7 
Water extractive value 6.7 
 
Table 2. Phytochemical presents in extract Scindapsus 
officinalis  Roxb 
Test for Ethanolic extract 
Alkaloids + 
Carbohydrates - 
Glycosides + 
Phenols and tannins + 
Steroids + 
Terpenoids + 
Saponins - 
Flavonoid + 
      (+) = present, (-) = absent 
Table 3. Percentage of phytoconstituents present in 
Scindapsus officinalis  Roxb 
Constituents 
presents  
Quantity of phytoconstituents 
in (%) 
Alkaloids 10.32 
Phenols 3.33 
Flavonoids 8.32 
Tannin 2.68 
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Table 4. Effect of Extract on animal for clinical observation 
Sample 
Name  
Extract Scindapsus officinalis  Roxb Species of Animal Rat 
Standar
d 
 Glibenclamide Gender of Animal Wistar 
Animal 
ID 
Days 
Days 
1 2 3 4 5 6 7 8 9 1
0 
1
1 
12 1
3 
1
4 
15 1
6 
1
7 
1
8 
1
9 
2
0 
2
1 
2
2 
2
3 
2
4 
2
5 
2
6 
2
7 
2
8 
2
9 
Group -1  
GP1 - 
1M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP1 - 
2M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP1 - 
3M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP1 - 
4M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP1 - 
5M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP1 - 
6M 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Group - 2  
GP2 - 
1M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP2 - 
2M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP2 - 
3M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP2 - 
4M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP2 - 
5M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP2 - 
6M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Group - 3  
GP3 - 
1M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP3 - 
2M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP3 - 
3M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP3 - 
4M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP3 - 
5M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP3 - 
6M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
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Table 5 Effect of Extract on animal for clinical observation 
Sample 
Name  
Scindapsus officinalis  Roxb Species of Animal Rat 
Standar
d 
 Glibenclamide Gender of Animal Wistar 
Animal 
ID 
Days 
Days 
1 2 3 4 5 6 7 8 9 1
0 
1
1 
1
2 
1
3 
1
4 
1
5 
1
6 
1
7 
1
8 
1
9 
2
0 
2
1 
2
2 
2
3 
2
4 
2
5 
2
6 
2
7 
2
8 
2
9 
Group - 4 
GP4 - 
1M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP4 - 
2M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP4 - 
3M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP4 - 
4M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP4 - 
5M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP4 - 
6M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Group -5 
GP5 - 
1M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP5 - 
2M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP5 - 
3M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP5 - 
4M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP5 - 
5M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP5 - 
6M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
Group - 6 
GP6 - 
1M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP6 - 
2M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP6 - 
3M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP6 - 
4M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP6 - 
5M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
GP6 - 
6M 
1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 
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Histopathology  
Group 1 
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Fig 1. Histopathology of group 1 
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Group 2 
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Fig 2. Histopathology of group 2 
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Group 3 
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Fig 3. Histopathology of group 3 
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Group 4 
Fig 4. Histopathology of group 4 
 
 
 
 
Brain  Heart 
 
 
 
Lungs  Liver 
 
Kidney 
Tiwari et al                                                                                                      Journal of Drug Delivery & Therapeutics. 2019; 9(4-s):1072-1086 
ISSN: 2250-1177                                                                                  [1081]                                                                                 CODEN (USA): JDDTAO 
Group 5 
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Fig 5. Histopathology of group 5 
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Group 6 
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Fig 6. Histopathology of group 6 
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Table 6. Effect of ethanolic extracts of Scindapsus officinalis  Roxb.on oral glucose tolerance in normal rats 
Gr. 
Treatment 
and dose 
Blood glucose concentration (mg/dl) % decrease 
at end of 3hr 
0 min 30 min 60 min 120 min 180 min 
I 
Normal 
Control 
83.75 ± 0.47 86.50 ± 0.84 88.50 ± 1.56 83.50 ± 0.98 86.50 ± 1.47 -- 
II 
Solvent 
control 
90.50 ± 0.64 135.52 ± 0.64** 118.83 ± 0.85** 98.50 ± 0.61** 91.50 ± 0.24** -- 
III 
Glibenclamide 
(5mg/kg) 
89.43 ± 0.40 95.50 ± 1.04** 81.53 ± 0.91** 72.50 ± 0.64** 62.51 ± 0.66** 30.10 
IV 
Eth. Ext. 
(200mg/kg) 
83.62 ± 1.78 98.25 ± 0.85** 97.61 ± 1.91** 93.50 ± 1.63** 92.13 ± 0.95 6.22 
V 
Eth. Ext. 
(400mg/kg) 
87.50 ± 0.89 107.31 ± 1.37** 102.32 ± 1.10** 94.50 ± 0.54* 91.50 ± 0.54 14.73 
 Values are expressed in MEAN ± S.E.M of six animals. One Way ANOVA followed by Dunnet’s t-test (t-value denotes statistical 
significance   at * p <0.05, ** p <0.01 respectively, in comparison to group-II) 
 
 
Fig.7 Effect of ethanolic extracts of Scindapsus officinalis  Roxb. on oral glucose tolerance in normal rats 
 
Effect of the extracts on blood glucose level in 
streptozocine induce hyper glycemic rats (Acute and 
sub-acute models) 
Acute model (In single dose treated streptozocin induced 
hyperglycemic rats) 
The effects of ethanol and aqueous extracts on fasting blood 
glucose levels on single dose treated streptozocin induced 
diabetic rats are presented in table 5.11 The ethanol extracts 
at 200 mg/kg dose level registered 149.36, mg/dl at the end 
of 10 h of the study, while it was 132.59, mg/dl with dose 
level of 400 mg/kg. However, at the same time the standard 
drug glibenclamide at 5mg/kg showed 98.59 mg/dl of BGL. A 
dose dependent effect of the test extracts was observed. The 
ethanol and aqueous extracts of Scindapsus officinalis  Roxb. 
in both dose levels (200 and 400 mg/kg) showed a persistent 
decrease in blood glucose level till the end of 10 hr., while the 
standard drug glibenclamide showed a 66.65% decrease. The 
statistical significance of one way ANOVA showed significant 
reduction of BGL @ p<0.05 to 0.01 starting from 1 hr up to 
the end of 10 hr within the groups. The potency order of the 
test extracts towards the falling of BGL is ethanolic extract.
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Table 7.Effect of  extracts of Scindapsus officinalis  Roxb.on blood glucose level in single dose treated streptozocin 
induced hyperglycemic rats. 
Group
s 
Treatment 
and dose 
Blood Glucose Levels (mg/dl) %age 
decreas
e at 
10hrs 
0 hr 1 hr 2 hr 4 hr 6 hr 8 hr 10 hr 
I 
Normal 
Control 
93.09 ± 
1.38 
89.50 ± 
0.64 
88.50 ± 
1.67 
90.50 ± 1.78 
87.59 ± 
0.98 
88.67 ± 
2.14 
89.76 ± 
2.33 
-- 
II 
Diabetic 
Control 
(Tween + 
Water) 
307.5 ± 
4.34 
297.63 ± 
4.93** 
301.81 ± 
2.89** 
291.88 ± 
3.51** 
287.89 
± 
3.67** 
303.77 ± 
4.29** 
279.61 ± 
2.71** 
-- 
III 
Glibencamide 
(5mg/kg) 
295.7 ± 
2.17 
258.62 ± 
3.21** 
198.31 ± 
2.49** 
139.21 ± 
2.63** 
126.31 
± 
3.28** 
118.91 ± 
2.96** 
98.59 ± 
2.87** 
66.65 
IV 
Eth. Ext. 
(200mg/kg) 
363.2 ± 
3.98 
348.38  ± 
3.26 
307.53  
± 3.24 
240.79 ± 
3.81** 
211.44 
± 
2.59** 
163.53 ± 
4.28** 
149.36 ± 
3.71** 
58.87 
V 
Eth. Ext. 
(400mg/kg) 
382.7 ± 
4.15 
369.68  ± 
2.88 
309.81 ± 
2.36* 
222.37 ± 
3.77** 
153.69 
± 
3.91** 
141.84 ± 
3.28** 
132.59 ± 
2.93** 
65.35 
 
Effects of ethanolic fraction and hexane fractions of 
Scindapsus officinalis  Roxb.on serum lipid profile  
In streptozocin induced diabetic rats, the marked 
hyperglycemia is accompanied by hypercholesterolemia and 
hypertriglyceridemia. The table 5.19 illustrates the levels of 
serum lipid profile such as total cholesterol, total 
triglycerides, HDL, LDL, VLDL on 21st day of the study. The 
diabetic rats showed significant (p <0.01) increase level of 
all tested lipid profiles except HDL, which showed decreased 
value in a significant (p <0.05) extent.  
The ethanolic fraction and hexane fractions at 150 mg/dl 
showed 143.79, 141.45 mg/dl total triglyceride level at the 
end of 21-day of the study, while at the same day the 
standard drug glibenclamide at 5mg/kg dose showed 135.02 
mg/dl of total triglycerides. Similarly, by ethanolic fraction 
and hexane fractions at 150 mg/dl registered 58.99, 57.03 
mg/dl and 61.20 mg/dl total cholesterol, while at the same 
day of study glibenclamide showed 51.55 mg/dl total 
cholesterol level. 
Similarly the LDL level decreased to 24.98, 22.73 mg/dl and 
25.08 mg/dl and VLDL level was decreased to 21.96, 20.93 
mg/dl and 22.75 mg/dl by ethanolic fraction and hexane 
fractions while standard drug glibenclamide at 5mg/kg dose 
decreased 14.42 mg/dl, LDL level and 18.73 mg/dl, VLDL 
level. In diabetic rats the HDL level decreased, which was 
increased to 15.67, 16.33 mg/dl and 14.33 mg/dl by the 
ethanolic fraction and hexane fractions, while glibenclamide 
increase HDL level upto19.05 mg/dl.    
The decreased in TG, TC, LDL and VLDL level, while 
increased in HDL level  by test extract and both fractions, in 
different test days showed a statistical significant of p <0.05 
to p<0.01, while analyzed by using ANOVA followed by 
Dunnett’s t-test. The extent of decrease lipid parameters 
except HDL of the 21-days treated rats were glibenclamide 
followed by ethanolic fraction and hexane fractions treated 
groups. 
 
Table 8. Effect of ethanolic fraction and hexane fractions of Scindapsus officinalis  Roxb.on serum lipid profile on 
treated streptozocin induced diabetic rats. 
Groups Treatments & Dose TG (mg/dl) TC (mg/dl) LDL (mg/dl) VLDL (mg/dl) HDL (mg/dl) 
I 
Solvent control (tween+ 
water) 
90.22 ± 2.08 43.10 ± 2.64 9.46 ± 3.10 11.53 ± 0.30 22.00 ± 0.57 
II Diabetic control 231.33 ± 1.85 77.19 ± 1.20 36.19 ± 3.60 30.87 ± 0.58 8.33 ± 0.88 
III 
Glibenclamide 
(5mg/kg) 
135.02 ± 3.71** 51.55 ± 6.50** 14.42 ± 3.74** 18.73 ± 1.60** 19.05 ± 0.57** 
IV 
Ethanolic 
fraction(150mg/kg) 
143.79 ± 3.42** 58.99 ± 2.53* 24.98 ± 1.63* 21.96 ± 0.78* 15.67 ± 1.37** 
V 
hexane fraction (150 
mg/kg) 
141.45 ± 4.40** 57.03 ± 2.08* 22.73 ± 1.61* 20.93 ± 0.92* 16.33 ± 0.33** 
Values are expressed in MEAN ± SEM of six animals. One Way ANOVA followed by Dunnet’s t-test (t-value denotes statistical 
significance at * p <0.05, ** p <0.01 respectively, in comparison to diabetic control group). 
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Fig.8 Effect of ethanolic fraction and hexane fractions of Scindapsus officinalis  Roxb. on serum lipid profile on treated 
streptozocin induced diabetic rats. 
 
CONCLUSION 
Protocol for general procedures and use of animals for 
conducting this study in rat has been reviewed and approved 
by the Institutional Animal Ethics committee (IAEC vide 
protocol number 870/PO/Re/S/05/CPCSEA). Body weights 
will be recorded on the day 1 of acclimatization and on the day 
of randomization; on Day 1 (prior to dosing) and on Days 7 
and 14 during the experimental period. Diabetes was induced 
in rats with an intraperitoneal injection of STZ ((40  mg/kg 
bwt) freshly prepared in 0.1 M sodium citrate buffer (PH 7) 
after overnight  fasting. The rats exhibited diabetes after 5 
days (i.e., fasting blood glucose concentration, >300 mg/dl) 
and were selected for the treatment with Scindapsu sofficinalis. 
Antihyperglycemic activity of ethanolic extracts in glucose-
loaded animals (oral glucose tolerance test) performed as An 
oral glucose tolerance test (OGTT) was performed on diabetic 
rats by feeding glucose (5 g/kg) per os. The ethanol extracts at 
200 mg/kg dose level registered 149.36, mg/dl at the end of 
10 h of the study, while it was 132.59, mg/dl with dose level of 
400 mg/kg. The ethanol extracts of Scindapsus officinalis  Roxb. 
in both dose levels (200 and 400 mg/kg) showed a persistent 
decrease in blood glucose level till the end of 10 hr., while the 
standard drug glibenclamide showed a 66.65% decrease. The 
ethanolic fraction and hexane fractions at 150 mg/dl showed 
143.79, 141.45 mg/dl total triglyceride level at the end of 21-
day of the study, while at the same day the standard drug 
glibenclamide at 5mg/kg dose showed 135.02 mg/dl of total 
triglycerides. So above results and observed data concluded 
the fruits extract of Scindapsus officinalis  possess the 
significant anti-diabetic and anti-hyperlipidemic activity. 
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